Marksans Pharma Ltd
NSE:MARKSANS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
132.95
353.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Marksans Pharma Ltd
Marksans Pharma Ltd
Cash Interest Paid
Marksans Pharma Ltd
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Marksans Pharma Ltd
NSE:MARKSANS
|
Cash Interest Paid
₹47.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash Interest Paid
₹2.9B
|
CAGR 3-Years
28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cash Interest Paid
₹442.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash Interest Paid
₹2.2B
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash Interest Paid
₹3.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Cash Interest Paid
₹261.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Marksans Pharma Ltd
Glance View
Marksans Pharma Ltd. is a prominent player in the global pharmaceutical landscape, with its roots deeply embedded in the meticulous world of drug formulation and manufacturing. The company weaves its narrative through a robust portfolio that spans various therapeutic segments, including pain management, oncology, cardiovascular health, and anti-diabetic medications. By navigating the complexities of regulated markets such as the United States, the United Kingdom, and Australia, Marksans has engineered a business model that emphasizes quality, compliance, and innovation. This framework allows the company not only to design and develop a diverse array of generic pharmaceutical products but also to efficiently cater to a global clientele through its cost-effective yet high-quality manufacturing processes. Central to Marksans' success is its strategic integration of research and development with flexible manufacturing capabilities, housed in state-of-the-art facilities across Goa and India. These facilities, certified by leading international regulatory bodies, enable Marksans to maintain a competitive edge in both product delivery and diversification. By leveraging strategic partnerships and continuously expanding its product portfolio, it thrives in the dynamic pharmaceutical market. Revenue generation flows seamlessly through its vertically integrated operations, which streamline the journey from drug conception to distribution. Through these concerted efforts, Marksans not only bolsters its financial standing but also contributes significantly to the broader field of global healthcare, aligning economic performance with a commitment to health and well-being.
See Also
What is Marksans Pharma Ltd's Cash Interest Paid?
Cash Interest Paid
47.3m
INR
Based on the financial report for Sep 30, 2024, Marksans Pharma Ltd's Cash Interest Paid amounts to 47.3m INR.
What is Marksans Pharma Ltd's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 3Y
-12%
Over the last year, the Cash Interest Paid growth was -5%. The average annual Cash Interest Paid growth rates for Marksans Pharma Ltd have been -12% over the past three years .
You don't have any saved screeners yet
